Patients who undergo autologous peripheral blood stem cell (PBSC) transplantation experience multiple symptoms that adversely affect quality of life. We assessed symptoms during the acute phase of autologous PBSC transplantation to determine the severity of individual symptoms and to determine overall symptom profiles in 100 patients with multiple myeloma or non-Hodgkin's lymphoma. Study subjects completed the blood and marrow transplantation module of the M. D. Anderson Symptom Inventory before hospitalization, during conditioning, on day of transplantation, at nadir (the time of lowest white blood cell count) and on day 30 posttransplantation. Additional symptom, quality-of-life and medical status measures were collected. Symptom means were mild at baseline, intensified during conditioning, peaked at nadir and decreased by day 30. At nadir, the most severe symptoms for the entire patient sample were lack of appetite, fatigue, weakness, feeling sick, disturbed sleep, nausea and diarrhea. Cancer diagnosis was a significant predictor of changes in symptoms over time. The patterns of fatigue, pain, sleep disturbance and lack of appetite were significantly different for patients with multiple myeloma as compared with patients with nonHodgkin's lymphoma.
Introduction
A number of studies in the past 20 years, including several comprehensive reviews, [1] [2] [3] [4] [5] examined the impact of bone marrow or peripheral blood stem cell (PBSC) transplantation on patients' quality of life and psychosocial adjustment. Although most of these studies focused on the posttransplantation period, several studies have found that the greatest impact on quality of life is found in the acute phase (first 30 days) of transplantation. Even before hospital admission, many patients report symptoms such as pain, fatigue, depression and anxiety. [6] [7] [8] [9] [10] In a descriptive study of patients with multiple myeloma scheduled for autologous SCT (stem cell transplantation), more than half of the subjects reported pain, fatigue and impaired physical function. 11 After hospital admission, patients experience symptoms related to a rigorous conditioning regimen followed by transplantation. McQuellon et al. 12 found that hospitalized patients undergoing autologous or allogeneic transplantation reported decreased quality of life, lack of appetite and frequent fatigue. Persistent pain and mild to moderate emotional distress were reported in small samples of patients with lymphoma throughout hospitalization for autologous transplantation. 13, 14 Syrjala et al. 15 followed a large sample of patients for 25 days after autologous or allogeneic transplantation. The patients reported mucositisinduced pain that peaked in intensity about 7 days after transplantation. In a prospective study of patients undergoing autologous or allogeneic transplantation, Prieto et al. 16 found that most patients reported a decline in physical health status and increases in symptoms during hospitalization.
In sum, research has found that most patients report symptoms and diminished overall quality of life during the acute phase of autologous transplantation. [17] [18] [19] [20] [21] [22] [23] Most studies have focused on quality of life or specific symptoms such as pain, fatigue, or depression and did not report overall symptom profiles. Several studies have identified nadir (the point of lowest white blood cell count (WBC)) as the time when individual symptoms were most severe; 6, 16, 17 other studies have found that biological and psychosocial factors were significant predictors of individual symptoms but did not evaluate cancer diagnosis as a predictor of overall symptom burden. 15, 24 Longitudinal studies with adequate sample sizes are needed to provide a comprehensive assessment of the symptoms experienced by patients who have undergone PBSC transplantation and to identify factors associated with symptom burden during the acute phase. [25] [26] [27] The objectives of our study were to (a) assess the symptom burden (i.e., symptom intensity and symptom-related interference) of patients during the acute phase of autologous transplantation, 27 and (b) identify predictors of high levels of symptom burden. On the basis of previous studies of individual symptoms, 6, 16, 17 we hypothesized that symptom intensity would increase post-transplantation and be most severe at nadir. We also predicted that symptomrelated interference in daily life would be most severe at nadir.
Patients and methods

Patient sample
The subjects were 100 patients scheduled to receive autologous PBSC transplantations at The University of Texas M. D. Anderson Cancer Center. Patients were recruited in the outpatient clinic before admission to the hospital for their pretransplantation conditioning regimen. Eligible patients were at least 18 years of age, spoke English, and could see and hear well enough to complete the assessment measures. Patients were excluded from the study if they had a current diagnosis of psychosis or dementia. Of the 148 eligible patients approached, 100 (68%) agreed to participate in the study and provided written informed consent. The study was approved by M. D. Anderson Cancer Center's Institutional Review Board.
The conditioning regimen for the patients with multiple myeloma consisted of melphalan or melphalan plus cyclophosphamide and topotecan (one patient received cytoxan, busulfan and thiotepa). The patients with nonHodgkin's lymphoma received BEAM (carmustine, etoposide, cytarabine, melphalan) or BEAM, cytoxan, or cyclophosphamide combined with rituxan.
Assessment method
Patients enrolled in the study completed a paper-and-pencil version of the blood and marrow transplantation module of the M. D. Anderson Symptom Inventory (MDASI-BMT) and other assessment measures, as detailed below, before commencing their conditioning regimen of high-dose chemotherapy (baseline). The research nurse asked patients to complete additional paper-and-pencil MDASI-BMT assessments on the third to fourth day of the conditioning regimen, on the day of transplantation and on the day of nadir as identified by the treatment team. Patients also completed the MDASI-BMT and other assessment measures at approximately 30 days post-transplantation. Project staff reminded patients that the symptom data were being collected for research purposes only and encouraged patients to report all symptoms to their physicians. Patients were carefully educated at baseline to report immediately any symptoms that could indicate potentially serious conditions.
Assessment measures
Measure of symptom burden: The MDASI-BMT. The M. D. Anderson Symptom Inventory (MDASI), a brief, easily understood measure of symptom severity and symptomrelated interference in daily life, was developed to assess symptom burden in patients with cancer. 28 In addition to the core MDASI, which assesses symptoms experienced in general, we have developed modules to assess the symptoms of patients with particular cancer diagnoses or specified treatments. The MDASI-BMT, designed in consultation with physicians and nurses in M. D. Anderson's Department of Stem Cell Transplantation and Cellular Therapy, assesses the symptoms they identified as important to monitor post-transplantation.
The MDASI-BMT measures 14 symptoms: pain, fatigue, weakness, nausea, diarrhea, mouth sores, shortness of breath, lack of appetite, feeling physically sick, disturbed sleep, difficulty paying attention, sadness, distress and bleeding. Also included are five interference items assessing symptom-related interference in general activity, mood, walking, relations with other people and enjoyment of life. The MDASI-BMT demonstrated good internal reliability in this study, with coefficient values of 0.86 and 0.82 for the symptom and interference scales, respectively, at the baseline assessment. At the nadir assessment, the coefficient values were 0.91 for the symptom scale and 0.90 for the interference scale. The MDASI-BMT has demonstrated both sensitivity to treatment status and the ability to discriminate between patients receiving high-dose chemotherapy followed by transplantation and patients receiving conventional chemotherapy or receiving no active treatment. 28, 29 In the present study, both symptom severity subscales (Po0.001) and symptom interference subscales (Po0.001) showed significant quadratic effects (highest point being nadir) across time.
Measure of mood: Profile of Mood States. The Profile of Mood States (POMS) is a standardized, reliable self-report instrument validated for use in the general population and in specific medical and psychiatric populations. 30, 31 Higher scores indicate greater mood disturbance. Subscale scores assess anxiety, depression, anger, vigor, fatigue and confusion. We used the 30-item short form, which retains the same subscales and response-option format (a 0-4 scale) as the 65-item version. A total mood disturbance score was calculated as the sum of the six subscale scores. The POMS has been used repeatedly in studies of cancer patients, 32, 33 and the short form's reliability and validity have been demonstrated. 30 The POMS was administered at baseline and on day 30 post-transplantation.
Measure of quality of life: Functional Assessment of Cancer Therapy-Bone Marrow Transplant. Quality of life was measured by the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), 12, 34 which has 27 general questions and 23 questions specific to blood or marrow transplantation. Patients rate all items using a 5-point scale ranging from 'not at all' to 'very much'. The measure yields information about total quality of life and the dimensions of physical well-being, social/ family well-being, emotional well-being, functional wellbeing and transplantation-specific concerns. The FACT-BMT was administered at baseline and on day 30 posttransplantation.
Measure of functional status: The Eastern Cooperative
Oncology Group Performance Status. The Eastern Cooperative Oncology Group Performance Status (ECOG PS) was used to assess the health care provider's estimate of the patient's functional status at each time point. 35 The ECOG PS scale is a 5-point measure of functional ability, ranging from fully active to completely disabled. The ECOG PS has demonstrated excellent reliability and validity in numerous clinical trials and descriptive studies. 36, 37 Laboratory variables. Laboratory variables that might affect patient symptoms and outcomes were collected from the patients' medical records at each time point. These variables included complete blood count with differential, platelet count, electrolytes, creatinine, blood urea and nitrogen, and total bilirubin and liver enzymes. The laboratory variables included in the analyses were identified by transplantation physicians as potentially having an effect on patient symptoms and outcomes.
Data analysis
Descriptive statistics were calculated for demographic characteristics of the patient sample and for symptom responses. On the basis of our previous work with pain and fatigue, 38, 39 we provisionally categorized symptoms as mild (ratings of 0-4 on the MDASI-BMT's 0-10 scale), moderate (ratings of 5-6) or severe (ratings of 7-10). A symptom severity score was calculated as the mean intensity of the 14 MDASI-BMT symptom scores. A symptom interference score was computed as the mean of the five MDASI-BMT interference items.
Repeated measures analyses of variance (ANOVA) with the within-subject factor of time and the between-subjects factor of cancer-diagnosis group (multiple myeloma or non-Hodgkin's lymphoma) were used to evaluate changes in symptom intensities and symptom-related interference across time. Covariates (demographics, mood, quality of life, treatment-related variables, laboratory measures) that might influence symptom intensity and interference were included. A 0.05 level of significance was used for each of the symptoms under the repeated measures model. Sensitivity analyses were made by replacing missing data with last observation carried forward and redoing the repeated measures ANOVA. Table 1 presents demographic and disease-related characteristics for the patient sample.
Results
MDASI-BMT symptom severity and interference
The repeated measures ANOVA for symptom severity scores (Po0.001) and symptom interference scores (Po0.001) showed only a main effect for time. None of the potential covariates (demographics, mood, quality of life, cancer diagnosis, treatment-related variables and laboratory measures) were significant. The mean symptom severity and symptom interference scores were significantly greater at nadir compared with baseline levels. Symptom severity and interference decreased after nadir. By day 30 post-transplantation, mean severity and interference scores did not differ significantly from baseline levels. Table 2 presents the mean MDASI-BMT symptom and interference scores across the five time points. Symptom means were in the mild range at baseline, before the conditioning regimen. At nadir, symptoms with the highest mean intensities were lack of appetite, fatigue, weakness, feeling physically sick, disturbed sleep, nausea and diarrhea. Patients also reported mild to moderate symptomrelated interference during the first 30 days after transplantation. Symptom-related interference was most intense at nadir, with general activity, walking and enjoyment of life reported as the most affected. At day 30, the means for symptom-related interference were comparable to baseline levels. Table 3 presents the percentages of patients reporting each symptom as moderate (ratings of 5-6) or severe (ratings of 7-10) at each time point. 38, 39 At baseline, 29% of the patients reported moderate to severe fatigue and 21% reported moderate to severe pain. The frequency of moderate to severe symptoms increased over time and peaked at nadir. Over half of the patients reported moderate to severe fatigue, weakness and lack of appetite at nadir. Feeling physically sick, disturbed sleep, nausea and diarrhea were described as moderate or severe by more than one-third of the patients at nadir.
The repeated measures ANOVA for fatigue severity revealed a significant time-by-cancer-diagnosis interaction (P ¼ 0.048). Results shown in Table 4 indicate that none of the other covariates were significant predictors. shows the varying fatigue patterns by cancer diagnosis. At baseline, during the conditioning regimen and at day 30 post-transplantation, the patients with non-Hodgkin's lymphoma reported higher levels of fatigue than the patients with multiple myeloma. At the time of transplantation and at nadir, however, the fatigue levels of the two groups were comparable.
The repeated measures ANOVA for sleep disturbance revealed a significant time-by-cancer-diagnosis interaction (P ¼ 0.02). As shown in Table 4 , none of the other covariates were significant predictors. Figure 2 illustrates the varying patterns of sleep disturbance by cancer diagnosis. The patients with multiple myeloma reported lower levels of disturbed sleep during conditioning, at transplantation and at nadir compared with the patients with non-Hodgkin's lymphoma. The repeated measures ANOVA for lack of appetite revealed a significant time-by-cancer-diagnosis interaction (P ¼ 0.02). Significant covariates were the patients' reported quality of life and mood disturbance at baseline (Table 4 ). Figure 3 shows the differing patterns in lack of appetite across time by cancer diagnosis. Lack of appetite was more severe during conditioning and at nadir for patients with non-Hodgkin's lymphoma than for patients with multiple myeloma. At the other time points, the severity of decreased appetite was comparable for the two cancer groups.
The repeated measures ANOVA for pain severity revealed a significant time-by-cancer-diagnosis interaction (P ¼ 0.008). Results shown in Table 4 indicate that none of the other covariates were significant predictors. Figure 4 depicts the varying pain patterns by cancer diagnosis. At baseline and at day 30 post-transplantation, the patients with multiple myeloma reported more severe pain than did the patients with non-Hodgkin's lymphoma. At nadir, however, reported pain levels for the patients with nonHodgkin's lymphoma were higher than for the patients with multiple myeloma. Sensitivity analyses replacing missing data with the last observation carried forward showed essentially the same results as the complete case repeated measures ANOVAs for symptom severity, symptom interference and individual symptoms. Only three patients were lost to follow-up before nadir. An additional nine patients were lost by the time of the last assessment at day 30 post-transplantation.
Discussion
Our study provided a comprehensive assessment of 14 physical, affective and cognitive symptoms during the acute phase of autologous PSCT transplantation. Mean symptom intensities were mild at baseline, increased gradually during conditioning and transplantation and peaked at WBC nadir. This pattern of symptom change over time was demonstrated by nine of the 14 symptoms assessed in the study. Pain, shortness of breath, emotional distress, sadness and bleeding were less variable over time. The pain data are consistent with the results of a previous study of autologous transplantation, in which most patients experienced mild to moderate persistent pain during the acute phase. 13 Symptoms with the highest mean intensities at nadir were lack of appetite, fatigue, weakness, feeling physically sick, disturbed sleep, nausea and diarrhea. For most patients, the majority of symptoms had returned to baseline levels or lower by day 30 post-transplantation. The intensities of nausea, lack of appetite, weakness and feeling physically sick remained elevated compared with baseline levels.
The longitudinal course of symptom interference paralleled that of symptom intensity. At baseline, most patients reported mild symptom-related interference in their general activity, walking, mood, relationships and enjoyment of life. Symptom-related interference gradually increased and was most intense at nadir, with general activity, walking and enjoyment of life reported as most affected. By day 30 post-transplantation, mean symptom-related interference had returned to baseline levels.
Patients' mean symptom intensity scores were in the mild to moderate range during the first 30 days. Mean intensities of lack of appetite, fatigue and weakness were in the moderate range at nadir. The remaining mean symptom intensities were in the mild range. Further analysis, however, revealed that a significant percentage of patients was experiencing moderate or severe symptoms. At baseline, 29% of patients reported moderate to severe fatigue and 21% reported moderate to severe pain. These results are consistent with previous findings documenting a high level of individual symptoms for many patients scheduled for transplantation. [6] [7] [8] [9] [10] By nadir, more than half of the patients reported moderate or severe fatigue, weakness and lack of appetite. Other symptoms at nadir were frequently reported as moderate or severe, including disturbed sleep, feeling physically sick, nausea and diarrhea. These results indicate that many patients may benefit from more aggressive symptom management during the acute phase of transplantation, especially at nadir.
The symptom patterns over time demonstrated by patients with non-Hodgkin's lymphoma differed somewhat from those shown by patients with multiple myeloma. One advantage of repeated longitudinal symptom assessment is the ability to identify differences among disease groups. Although the mean symptom intensity and symptomrelated interference scores of the two cancer groups were comparable across time, the patterns of several individual symptoms were variable for the two groups. The patients with multiple myeloma reported more intense pain at four of the five assessments in the study, most likely because of the bone involvement associated with their disease. At nadir, however, the patients with non-Hodgkin's lymphoma reported more severe pain. The reasons for the difference at nadir are not clear but may be related to the intense conditioning regimens and associated mucositis experienced by patients with non-Hodgkin's lymphoma. The lymphoma patients also reported more severe fatigue at baseline and during conditioning and more intense sleep disturbance during the conditioning, transplantation and nadir time points than did the myeloma patients. During conditioning and nadir, the lymphoma patients' lack of appetite was described as more severe. These differences in symptom intensities between the two cancer groups may have been owing to differences in disease or treatment history and conditioning regimens. By day 30, the levels of sleep disturbance and lack of appetite of the patients with non-Hodgkin's lymphoma were comparable to those of the patients with multiple myeloma. However, the pain levels of the myeloma patients at day 30 were higher than the levels reported by the lymphoma patients.
Our study had several limitations. The sample size was moderate and included patients with different treatment histories. Previous treatments may have influenced the severity of patients' symptoms at baseline and their subsequent course. Analyses of patient subgroups based on treatment history, however, did not indicate significant differences in symptom severity or pattern. Additional research with larger samples is needed to explore the differing symptoms experienced by multiple myeloma patients and non-Hodgkin's lymphoma patients who undergo autologous transplantation. Future research can also identify differing clusters of symptoms in subgroups of patients who undergo stem cell transplantation.
In sum, our study described the longitudinal pattern of symptoms and symptom-related interference in patients with multiple myeloma or non-Hodgkin's lymphoma during the acute phase of autologous transplantation. Although most patients reported symptom severities in the mild to moderate range, subgroups of patients reported moderate to severe symptoms and likely could have benefited from additional symptom treatments. Patients demonstrated differing patterns of symptoms during the acute phase of PBSC transplantation that were related to their cancer diagnosis. Awareness of symptom patterns over time for patients with multiple myeloma or non-Hodgkin's lymphoma may help to optimize symptom management.
